In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Ventures: Building A Venture Portfolio in Devices

Executive Summary

Corporate venture investing has become an increasingly important source of capital as traditional venture firms remained squeezed. In devices, the latest entrant into the field is Abbott Ventures, which sees itself as an extension of Abbott's internal efforts to build its device pipeline, favoring mid-stage deals in technology and therapeutic areas that fit strategically with Abbott's existing device businesses.

You may also be interested in...

Abbott Moves into Heart Valves with Evalve Deal

The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.

Abbott Vascular: The Now-Ready-For-Prime-Time Player

Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.

Abbott Makes Its Play In Stents

In building its interventional cardiology business, Abbott Laboratories has generally avoided going head-to-head with any of the major cardiovascular device players in traditional product markets such as coronary stents. But that is about to change. Its acquisition of Biocompatibles' stent business marks Abbott's entry into cardiology's major league as the company attempts to establish itself in what looks to be the next blockbuster cardiovascular device product market--drug-coated stents.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts